Search clinical trials for: Iodine -131 Anti-B1 Antibody

Total 99084 results

Corixa Corporation
GlaxoSmithKline

Unknown

Expanded Access Study of Iodine-131 Anti-B1 Antibody

Non-Hodgkin's Lymphoma

United States
Corixa Corporation

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP

Non-Hodgkin's Lymphoma

United States
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement

Non-Hodgkin's Lymphoma

United States
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United Kingdom, United States
Corixa Corporation

Completed

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
GlaxoSmithKline

Completed

Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab

Lymphoma, Non-Hodgkin
Corixa Corporation
GlaxoSmithKline

Unknown

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
GlaxoSmithKline

Completed

Dosimetry/Validation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies (RIT-II-001)

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
University of Nebraska
National Cancer Institute (NCI); Coulter Pharmaceutical, Inc.

Terminated

Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement

Lymphoma, Non-Hodgkin
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

Lymphoma, Mantle-Cell
GlaxoSmithKline

Completed

Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma

Lymphoma, Non-Hodgkin

United States, France, United Kingdom
GlaxoSmithKline

Completed

Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
University of Nebraska

Completed

Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma

Lymphoma

United States
GlaxoSmithKline

Completed

Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.

Lymphoma, Non-Hodgkin
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Shenzhen Second People's Hospital

Unknown

Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

Multiple Myeloma in Relapse

China
Loewenstein Hospital
Meir Medical Center

Unknown

LMWH-VTE Prophylaxis for Survivors of Acute Ischemic Stroke- Assessment of Standard Dosing Regimen

Stroke

Israel
BioMérieux

Completed

Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa

Malaria | Dengue | Chikungunya

Burkina Faso, Côte D'Ivoire
PharmAbcine
Merck Sharp & Dohme LLC; Novotech (Australia) Pty Limited

Not yet recruiting

Study to Assess the Safety, Tolerability, and Blood Concentration of PMC-309 (MarkV-01)

Advanced or Metastatic Solid Tumors

Australia
Abramson Cancer Center at Penn Medicine
Xencor, Inc.

Active, not recruiting

XmAb20717 in Advanced Biliary Tract Cancers

Biliary Tract Cancer

United States
United Nations Office on Drugs and Crime (UNODC)
Polytechnique University of the Philippines; Anti-Drug Abuse Councils, LGUs...

Enrolling by invitation

Assessing the Feasibility of Providing a Family Skills Intervention "Strong Families" for Families in the Philippines. (SF_RCT_POPHL)

Family Relationship | Parenting Skills

Philippines
John Maris

Available

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Neuroblastoma | Childhood Metastatic Pheochromocytoma

United States
Cellectar Biosciences, Inc.

Active, not recruiting

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Pediatric Brain Tumor | DIPG | Pediatric Solid Tumor | Pediatric Lymphoma

United States, Australia, Canada
University of Nebraska

Completed

Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
University Hospital, Bordeaux

Completed

PilBouTox® Project: Button Battery Poisoning From Data Collected by French Poison Control Centres (PILBOUTOX)

Button Battery Poisoning

France
R3 Stem Cell
R3 Medical Research

Recruiting

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

Low Back Pain

United States
Kite, A Gilead Company
Arcellx, Inc.

Recruiting

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

United States
Stealth BioTherapeutics Inc.
ICON Clinical Research

Completed

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events (EMBRACE)

Reperfusion Injury | STEMI

United States, Hungary, Germany, Poland
University Hospital, Bordeaux

Completed

Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy (CANNEMUSS)

COVID-19 | Neuromuscular Diseases | Amyotrophy

France
University of Oxford
National Institute for Health Research, United Kingdom; 180 Life Sciences

Completed

The Anti-Freaze-F Study- "Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study" (Anti-FreazeF)

Frozen Shoulder

United Kingdom
Assistance Publique - Hôpitaux de Paris

Completed

Testicular Function After Iodine 131 Therapy in Papillary Carcinoma Patients (SAPIRA)

Thyroid Neoplasms

France
University of Michigan Rogel Cancer Center
GlaxoSmithKline

Active, not recruiting

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Multiple Myeloma

United States
University Hospital of Ferrara

Recruiting

Analysis of Chemical Pattern Exhaled by Different Neoplasms Through Chemoresistive Nanostructured Sensors

Tumor, Solid

Italy
Cellectar Biosciences, Inc.

Recruiting

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

Multiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System Lymphoma

United States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)

Recruiting

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

High-Grade Glioma

United States, Canada
Cellectar Biosciences, Inc.

Withdrawn

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Glioma

United States
Texas Tech University

Completed

Adherence to Walking on an Alter G Anti-Gravity Treadmill

Severe Obesity

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); Cellectar Biosciences...

Active, not recruiting

CLR 131 Combined With Radiation for Head and Neck Cancer

Head and Neck Cancer

United States
Case Comprehensive Cancer Center

Completed

Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Centre Hospitalier Universitaire de Saint Etienne
Ministry of Health, France

Recruiting

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders (THERAMAG)

Anti-MAG Neuropathy

France
Sun Yat-sen University

Unknown

The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions

Hypothyroidism | Exophthalmos

China

Search clinical trials for: Iodine -131 Anti-B1 Antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations